Semaglutide heart signal meets FDA import and Medicare access shifts
Thursday, September 24, 2026 · 9 min
Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment.
Listen
Show notes
Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment.
In this episode
- Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! — EurekAlert!
Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! News Release 23-Sep-2026 # Weight loss alone does not explain lower heart disease for those on semaglutide image: Professor Helen Colhoun view more Credit: Helen Colhoun / European Society of Cardiology - The SELECT trial has already shown a 20% lower risk of heart disease for people with…
- China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended — BigGo
# China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended Published: 2026-09-22T13:35:30+00:00 Source: finance.biggo.com (finance.biggo.com) Language: en ## Story # China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended - Published: 2026-09-22T13:35:30.000Z - Updated: 2026-09-22T13:36:42.000Z - Author: BigGo Editorial Team -…
- Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint — AllSci
Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint # Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint Edited by Robert McTiernan· September 22, 2026· 2 min read Novo Nordisk's cagrilintide and semaglutide combination CagriSema delivered superior weight loss versus a lower dose of tirzepatide in type 2 diabetes and met its primary…
- 700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK — IBTimes UK
700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK ## Zepbound and Foundayo lead the market as Lilly captures 7 out of 10 new Medicare patients By Stephanie Cruz Published 24 September 2026, 1:50 AM BST Seniors get their weight-loss jabs for a $50 (£37) monthly copay under Medicare's Bridge programme, while drugmakers cash in on a…
- Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing — Pharma Manufacturing
Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing # Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity The Danish drugmaker plans to scale production capacity to supply oral obesity therapies to 15 million patients globally by the end of the decade. Greg Slabodkin Sept. 22, 2026 5 min read 6ab29f6e83303d83b9ca0b11 Novonordisk…